(131) IODINE-B1 RADIOIMMUNOTHERAPY OF ADVANCED NON HODGKIN'S LYMPHOMA

(131) 晚期非霍奇金淋巴瘤的碘 B1 放射免疫治疗

• 批准号: 6244592
• 负责人: MARK S. KAMINSKI
• 金额: $ 2.22万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-02-20 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6244592
• 关键词: CD antigens; clinical research; clinical trials; combination cancer therapy; dosage; drug adverse effect; drug screening /evaluation; human subject; human therapy evaluation; iodine; monoclonal antibody; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; nonHodgkin's lymphoma; radiotracer

The main purpose of this study is to determine the tumor response rate of a maximally tolerated radioimmunotherapeutic dose of a monoclonal anti-CD20 antibody labeled with 131-I in patients with B-cell lymphoma who have relapsed after or have failed to respond to conventional-dose chemotherapy. Other goals are to assess the tumor targeting potential and the toxicity of this radiolabeled anti-B-cell antibody.

本研究的主要目的是确定肿瘤缓解率 最大耐受放射免疫剂量的单克隆 131-I标记抗CD 20抗体在B细胞淋巴瘤中的应用 在常规剂量治疗后复发或无效的患者 化疗 其他目标是评估肿瘤靶向潜力 以及这种放射性标记的抗B细胞抗体的毒性